Skip to main content

Mifepristone Efficacious for Adenomyosis

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 14, 2023 -- For patients with adenomyosis, mifepristone is efficacious and has acceptable tolerability, according to a study published online June 12 in JAMA Network Open.

Xuan Che, Ph.D., from Zhejiang University in Hangzhou, China, and colleagues examined whether mifepristone is effective and safe for adenomyosis treatment in a multicenter trial conducted in 10 hospitals in China. A total of 134 patients with adenomyosis pain symptoms were enrolled and randomly assigned to receive mifepristone 10 mg or placebo once a day for 12 weeks. Overall, 126 patients were included in the efficacy analysis: 61 and 65 in the mifepristone and placebo groups, respectively.

The researchers found that the mean change in visual analog scale score after 12 weeks of treatment was −6.63 in the mifepristone group and −0.95 in the placebo group. The total remission rates for dysmenorrhea were significantly better in the mifepristone versus placebo group (effective remission: 91.8 versus 23.1 percent; complete remission: 88.5 versus 6.2 percent). Significant improvements were seen in all secondary end points in the mifepristone group, including menstrual blood loss, hemoglobin, CA125, platelet count, and uterine volume. No significant difference was seen between the groups in the safety analysis, and there were no reports of serious adverse events.

"Adenomyosis-associated dysmenorrhea intensity was significantly reduced after mifepristone treatment. Regardless of how severe the intensity of dysmenorrhea, the total efficacy for dysmenorrhea was satisfactory," the authors write. "Further research is still needed to determine the long-term safety and efficacy."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2023

Read this next

Prevalence of Endometriosis Increased With Cadmium Exposure

MONDAY, July 31, 2023 -- Cadmium exposure is associated with increased prevalence of endometriosis, according to a study published online July 24 in Human Reproduction. Mandy S...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.